- Home
- XAIR vs NERV Comparison
XAIR vs NERV Comparison
Compare XAIR & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- NERV
- Stock Information
- Founded
- XAIR 2011
- NERV 2007
- Country
- XAIR United States
- NERV United States
- Employees
- XAIR N/A
- NERV N/A
- Industry
- XAIR Medical/Dental Instruments
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- XAIR Health Care
- NERV Health Care
- Exchange
- XAIR Nasdaq
- NERV Nasdaq
- Market Cap
- XAIR 17.0M
- NERV 14.6M
- IPO Year
- XAIR N/A
- NERV 2014
- Fundamental
- Price
- XAIR $2.50
- NERV $2.14
- Analyst Decision
- XAIR Strong Buy
- NERV Hold
- Analyst Count
- XAIR 1
- NERV 1
- Target Price
- XAIR $11.00
- NERV $5.00
- AVG Volume (30 Days)
- XAIR 466.2K
- NERV 16.8K
- Earning Date
- XAIR 11-10-2025
- NERV 11-04-2025
- Dividend Yield
- XAIR N/A
- NERV N/A
- EPS Growth
- XAIR N/A
- NERV N/A
- EPS
- XAIR N/A
- NERV 1.48
- Revenue
- XAIR $4,782,000.00
- NERV N/A
- Revenue This Year
- XAIR $263.75
- NERV N/A
- Revenue Next Year
- XAIR $148.43
- NERV N/A
- P/E Ratio
- XAIR N/A
- NERV $1.42
- Revenue Growth
- XAIR 168.20
- NERV N/A
- 52 Week Low
- XAIR $2.02
- NERV $1.15
- 52 Week High
- XAIR $13.52
- NERV $2.83
- Technical
- Relative Strength Index (RSI)
- XAIR 52.02
- NERV 50.37
- Support Level
- XAIR $2.16
- NERV $2.06
- Resistance Level
- XAIR $2.53
- NERV $2.15
- Average True Range (ATR)
- XAIR 0.13
- NERV 0.13
- MACD
- XAIR 0.03
- NERV -0.00
- Stochastic Oscillator
- XAIR 91.89
- NERV 41.90
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.